Prot #MK-3475-426: A Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Axitinib versus Sunitinib Monotherapy as a First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcin

Project: Research project

Project Details

StatusActive
Effective start/end date2/22/172/28/23

Funding

  • DrugDev Inc. (Prot #MK-3475-426)
  • Merck Sharp & Dohme Corporation (Prot #MK-3475-426)